Skip to main content
. 2020 Jun 1;25(10):e1481–e1491. doi: 10.1634/theoncologist.2019-0982

Figure 2.

Figure 2

Identification of the LAR, IM, BLIS and MES subtypes by the protein expression of AR, CD8, FOXC1 and DCLK1 detected by immunohistochemistry, respectively. (A): Protein expression of AR, CD8, FOXC1, and DCLK1 detected by immunohistochemistry according to the mRNA‐based classification (BLIS, n = 82; IM, n = 45; LAR, n = 55; MES, n = 28). The p values are calculated using the Mann‐Whitney U test. (B): Receiver operating characteristic (ROC) curves for using the protein expression of AR, CD8A, FOXC1, and DCLK1 detected by immunohistochemistry to identify the corresponding subtypes. The sample number for each ROC curve is 210. ***p < .001, *p < .05.

Abbreviations: AR, androgen receptor; AUC, area under the curve; BLIS, basal‐like immune‐suppressed; CI, confidence interval; FPKM, fragments per kilobase of exon per million mapped fragments; IM, immunomodulatory; LAR, luminal androgen receptor; MES, mesenchymal.